Suzhou OSAI Biopharma’s L. crispatus Capsule Meets Phase III Endpoints in Bacterial Vaginosis Study
China-based Suzhou OSAI Biopharma Inc., a specialist in live biotherapeutic products (LBPs), has announced that...
Sanofi Abandons MZE001 Licensing Deal Following FTC Intervention Over Pompe Disease Monopoly Concerns
Sanofi (NASDAQ: SNY) has withdrawn from an agreement announced earlier this year to in-license the...
BMS Advances TIGITxCD96 Bispecific Antibody into Phase II Dose Expansion
Bristol Myers Squibb (BMS; NYSE: BMY) has advanced its development program for the TIGITxCD96 bispecific...
Sanofi Partners with Minapharm for Local Production of Anticoagulant Clexane in Egypt
Sanofi (NASDAQ: SNY) has entered into a partnership with Egyptian biotechnology company Minapharm to locally...
Sisram Medical’s Profhilo Accepted for Review by China’s NMPA
Sisram Medical Ltd (HKG: 1696), an Israel-based company within the Fosun Pharmaceutical Group (SHA: 600196),...
Staidson Pharmaceutical Initiates Clinical Study for ARDS Treatment STSA-1002
Staidson (Beijing) Pharmaceutical Co., Ltd (SHE: 300204), a Chinese pharmaceutical company, has announced the dosing...
Cryofocus Medtech Receives NMPA Approval for Complete Cardiac Cryoablation System
Cryofocus Medtech (Shanghai) Co., Ltd. (HKG: 6922), a Shanghai-based specialist in cryoablation treatment, has announced...
Staidson Pharmaceutical Halts Clinical Trial for Hepatitis B Drug Due to Efficacy Concerns
Staidson (Beijing) Pharmaceutical Co., Ltd (SHE: 300204), a Chinese pharmaceutical company, has announced the cancellation...
Zylox-Tonbridge Medical Technology’s ZENFLOW T18 Receives NMPA Marketing Approval
Zylox-Tonbridge Medical Technology (HKG: 2190), a developer of nerve and peripheral vascular interventional devices based...
Skyline Therapeutics’ Gene Therapy SKG0201 for SMA Gets Green Light from China’s NMPA
Skyline Therapeutics has received clinical trial approval from China’s National Medical Products Administration (NMPA) for...
Sichuan Biokin and Bristol Myers Squibb Ink USD 8.4 Billion Licensing Deal for ADC Candidate
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a Chinese pharmaceutical company, has announced a landmark...
Kangtai Biological Partners with Gennvax Egypt to Commercialize 13-Valent Pneumococcal Vaccine
Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601), a Chinese biopharmaceutical company, has entered into...
Haplox and Illumina Mark Milestone with Production of NextSeq 2000Dx-CN-HAP Sequencing System in China
Haplox Biotechnology Co., Ltd, a Chinese biotech firm, and US industry leader Illumina (NASDAQ: ILMN)...
CDE Requests Feedback on 77th Batch of Chemical Generic Reference Preparations by December 20
The Center for Drug Evaluation (CDE) is currently soliciting feedback on the 77th batch of...
Kelun-Biotech’s SKB264 NDA Accepted by NMPA for mTNBC, Poised to Be China’s First TROP2-targeted ADC
Sichuan Kelun Pharmaceutical Co., Ltd. (SHE: 002422) announced that its innovative drug development subsidiary, Sichuan...
Nona Biosciences Partners with Evive Biotech to Discover H2L2 Antibodies Using Harbour Mice Platform
Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has entered into a...
Chinese Biotech Precision Biotechnology Gets NMPA Green Light for Advanced Cancer Therapies
Chongqing Precision Biotechnology Co., Ltd, a Chinese biopharmaceutical company, has received approval from the National...
Bayer Partners with Salus Optima to Advance Precision Health Solutions for Healthy Aging
Bayer (ETR: BAYN), a German multinational pharmaceutical and life sciences company, has partnered with IT...
MSD Halts Phase III Trial of Keytruda Combo in NSCLC After Missing Primary Endpoints
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced the discontinuation of a Phase III...
Novartis Reports Kisqali Success in Reducing Recurrence Risk in Early Breast Cancer
Novartis (NYSE: NVS) has announced an update on the late-stage trial for its CDK4/6 inhibitor...